- Home
- PSN vs BBIO Comparison
PSN vs BBIO Comparison
Compare PSN & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSN
- BBIO
- Stock Information
- Founded
- PSN 1944
- BBIO 2015
- Country
- PSN United States
- BBIO United States
- Employees
- PSN N/A
- BBIO N/A
- Industry
- PSN EDP Services
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PSN Technology
- BBIO Health Care
- Exchange
- PSN Nasdaq
- BBIO Nasdaq
- Market Cap
- PSN 6.8B
- BBIO 8.0B
- IPO Year
- PSN 2019
- BBIO 2019
- Fundamental
- Price
- PSN $74.81
- BBIO $45.60
- Analyst Decision
- PSN Buy
- BBIO Strong Buy
- Analyst Count
- PSN 11
- BBIO 14
- Target Price
- PSN $83.67
- BBIO $58.85
- AVG Volume (30 Days)
- PSN 1.2M
- BBIO 3.3M
- Earning Date
- PSN 08-06-2025
- BBIO 07-31-2025
- Dividend Yield
- PSN N/A
- BBIO N/A
- EPS Growth
- PSN 50.29
- BBIO N/A
- EPS
- PSN 2.35
- BBIO N/A
- Revenue
- PSN $6,769,260,000.00
- BBIO $127,415,000.00
- Revenue This Year
- PSN N/A
- BBIO $102.05
- Revenue Next Year
- PSN $3.19
- BBIO $54.69
- P/E Ratio
- PSN $31.82
- BBIO N/A
- Revenue Growth
- PSN 16.61
- BBIO N/A
- 52 Week Low
- PSN $54.56
- BBIO $21.72
- 52 Week High
- PSN $114.68
- BBIO $45.48
- Technical
- Relative Strength Index (RSI)
- PSN 69.95
- BBIO 66.67
- Support Level
- PSN $66.06
- BBIO $41.80
- Resistance Level
- PSN $72.33
- BBIO $45.48
- Average True Range (ATR)
- PSN 1.77
- BBIO 1.57
- MACD
- PSN 0.54
- BBIO -0.01
- Stochastic Oscillator
- PSN 95.73
- BBIO 78.42
About PSN Parsons Corporation
Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.